PI3K Pathways Virtual Summit 2021
AUM Biosciences will be taking part in the PI3K Pathways Virtual Summit. This event will feature leading voices developing the next generation of safe and effective PI3K inhibitors.
AUM Biosciences, a global clinical-stage biopharmaceutical company focused on discovering, acquiring, and developing novel targeted therapeutics in oncology, is pleased to announce that Dr Harish Dave, Co-Founder and Chief Medical Officer, will be presenting about promising combination therapies involving co-targeting PIM Kinase and PI3K/mTOR. This event, hosted through LinkedIn, will take place on Wednesday, August 25th.
To access the virtual summit, please register HERE
About AUM Biosciences
AUM Biosciences is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. The management team has an extensive track record of selecting distinctive early stage assets, successfully exiting virtual biotech models, and have contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability and scalability.
For more information, please visit www.aumbiosciences.com